Drug Trial Radar · NCT07241234
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Apr 17, 2026
Primary completion
Jan 17, 2028
Study completion Jan 17, 2028
Sponsor
- Lead sponsor
- Agios Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the safety and tolerability of AG-181 in subjects with Phenylketonuria (PKU).
Conditions
- Phenylketonuria
Interventions
AG-181Drug
AG-181 film-coated tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Type, Severity, and Relationship to the Study DrugTime frame: Up to Day 42
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Indiana University
Indianapolis, Indiana · Recruiting
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
University of Texas Southwestern Medical Center (UTSW)
Dallas, Texas · Recruiting
Uniwersyteckie Centrum Kliniczne (Medical University of Gdansk)
Gdansk, Pomeranian Voivodeship, Poland · Recruiting
Centrum Wsparcia Badań Klinicznych Pomorskiego Uniwersytetu Medycznego w Szczecinie
Szczecin, West Pomeranian Voivodeship, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.